Anna Khvorova-Komar's Contact Details

Anna Khvorova-Komar's Company Details

SATOR Therapeutics

Cleveland, Ohio, United States • 2 Employees
Pharmaceuticals

SATOR uses multiple viruses selected from its panel based upon companion diagnostics which predict efficacy in a patient's cancer. The companion diagnostics identify and test biomarkers in the patient's tumor that predict responses to different SATOR viruses. Each applied virus escapes the adaptive immunity elicited by other non–related viruses. Furthermore, two or three non–related SATOR viruses utilizing different host–cell receptors can also be applied simultaneously to treat aggressive cancers and to lower the probability of relapses. SATOR uses nonpathogenic, nonengineered, naturally occurring human enterovirus strains which have been extensively tested in large clinical trials as live enterovirus vaccines for nonspecific protection against seasonal viral infections; no significant side effects or adverse events have been reported.SATOR's panel approach has been validated in mouse xenograft models of human cancers and in human compassionate use studies in a variety of advanced metastatic cancers: ovarian, brain, breast, cervical, colon/rectum, lung, pancreatic, prostate, renal, bladder, sarcoma, lymphoma, stomach, and esophageal cancer tumors.The orphan indication ovarian cancer has been chosen for initial development. Three SATOR viruses from our panel have been selected for further development based upon efficacy against multiple ovarian cancer cell lines and follow up testing against a variety of patient tissues.